Increasing demand for specialist care regarding chemsex

The phenomenon of chemsex

Chemsex involves taking specific drugs before or during sex, often in the context of prolonged sessions with multiple partners, which increases health risks. It has been most frequently studied among men who have sex with men (MSM). A recent article (1) by Georgiadis et al. shows that, worldwide, 22% of MSM have experience with chemsex. The figures are compiled from 238 studies involving a total of 380,505 participants. For at least five of the substances, the figures in Europe were consistently the highest in the world.

"For many people who engage in chemsex, it remains difficult to find appropriate support," says Tom Platteau, a sexologist at ITM. "Support services often focus solely on sex or solely on substance use, whereas it is precisely the combination of these factors that is crucial to providing people with effective support. With this centre, we aim to bridge that gap."

Science, healthcare and the community come together

How can researchers, healthcare providers, community organisations and people with personal experience work together to improve care and support? That was the central question during the International Chemsex Conference, organised by ITM from 3 to 5 March. Over three days, 242 participants from 25 countries exchanged research findings, practical experiences and ideas. "Chemsex is an international phenomenon," said Tom Platteau. "By sharing knowledge and experiences, we enhance the quality and humanity of care for people affected by this."